Media Releases

Quick Explore

Media Releases 2021
Cipla and Kemwell Biopharma announce execution of a joint venture agreement for developing, manufacturing and commercialising biosimilars
Cipla receives final approval for generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%)
Pharma Majors Collaborate for Clinical Trial of Investigational Oral Anti-Viral Drug Molnupiravir for COVID-19
Cipla receives final approval for generic version of Sunovion Pharmaceuticals, Inc.’s Brovana® (Arformoterol Tartrate Inhalation Solution 15 mcg/ 2mL)
Roche’s Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India
Cipla launches ‘ViraGen’ a polymerase chain reaction (Covid-19 RT-PCR) test
Cipla Enters into a Licensing Agreement with Lilly to Expand Access to COVID-19 Treatment in India
Roche receives Emergency Use Authorisation in India for its investigational Antibody Cocktail (Casirivimab and Imdevimab) used in the treatment of Covid-19
Cipla enters into a licensing agreement with MSD to expand access to investigational oral therapeutic drug for COVID-19 treatment
Cipla Therapeutics and SIGA Technologies Announce Strategic Partnership to support innovation and provide access to novel antibacterial drugs against biothreats
Cipla pledges support to ‘Terra Carta’, for a sustainable future
Cipla Gulf Expands Partnership with Alvotech for Commercialization of Biosimilars in Australia and New Zealand
Cipla receives final approval for generic version of GlaxoSmithKline’s IMITREX®
Cipla celebrates 85 years with the launch of its book ‘Caring For Life: The Cipla Story Since 1935’
Cipla champions its commitment to carbon neutrality with its 30 MW solar plant in Maharashtra